KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.
2020
TPS3149Background: Human papillomavirus 16 (HPV16) is the most prominent subtype across invasive head and neck cancers, as well as cervical cancer and other anogenital cancers (Saraiya M, et al. J ...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
1
Citations
NaN
KQI